Sharma, Kavita

Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity

Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,669

A Null Mutation in Murine CD36 Reveals an Important Role in Fatty Acid and Lipoprotein Metabolism

Febbraio, M., Abumrad, N. A., Hajjar, D. P., Sharma, K., Cheng, W., Pearce, S. F. A., & Silverstein, R. L. (1999) · Journal of Biological Chemistry

Cholesterol and Lipid MetabolismLipid metabolism and disorders

Cited by 769

Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes

Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 758

Heart Failure With Preserved Ejection Fraction

Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 742

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: A multicenter randomized trial

Nassif, M. E., Windsor, S. L., Borlaug, B. A., Kitzman, D. W., Shah, S. J., Tang, F., Khariton, Y., Malik, A. O., Khumri, T., Umpierrez, G., et al. (2021) · Nature Medicine

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 618

Heart Failure With Preserved Ejection Fraction: Mechanisms, Clinical Features, and Therapies

Sharma, K., & Kass, D. A. (2014) · Circulation Research

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 508

Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials

Butler, J., Shah, S. J., Petrie, M. C., Borlaug, B. A., Abildstrøm, S. Z., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Verma, S., et al. (2024) · The Lancet

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 386

Myocardial Gene Expression Signatures in Human Heart Failure With Preserved Ejection Fraction

Hahn, V. S., Knutsdottir, H., Luo, X., Bedi, K., Margulies, K. B., Haldar, S. M., Stolina, M., Yin, J., Khakoo, A. Y., Vaishnav, J., et al. (2021) · Circulation

Cardiovascular Function and Risk FactorsHeart Failure Treatment and Management

Cited by 291

Semaglutide and NT-proBNP in Obesity-Related HFpEF

Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Kitzman, D. W., Shah, S. J., Verma, S., Jensen, T. J., Einfeldt, M. N., Liisberg, K., et al. (2024) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 95

Recurrent Lactobacillus Bacteremia in a Patient With Leukemia

Ambesh, P., Stroud, S., Franzova, E., Gotesman, J., Sharma, K., Wolf, L., & Kamholz, S. (2017) · Journal of Investigative Medicine High Impact Case Reports

Probiotics and Fermented FoodsNeutropenia and Cancer Infections

Cited by 31

The rationale for testing drug combinations in aging intervention studies

Sharma, K., Wang, J., Jiang, Z., Klug, J., Darvas, M., M. Imai, D., Snider, T., Niedernhofer, L., & Ladiges, W. (2019) · Aging Pathobiology and Therapeutics

Genetics, Aging, and Longevity in Model OrganismsTelomeres, Telomerase, and Senescence

Cited by 4